Free Trial

Genmab A/S (GMAB) Competitors

Genmab A/S logo
$24.65 +0.23 (+0.94%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$24.74 +0.09 (+0.37%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GMAB vs. TAK, ARGX, ONC, BNTX, INSM, SMMT, TEVA, ASND, VTRS, and RDY

Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

Genmab A/S vs. Its Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Genmab A/S has a net margin of 37.53% compared to Takeda Pharmaceutical's net margin of 3.20%. Genmab A/S's return on equity of 21.03% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical3.20% 10.50% 5.10%
Genmab A/S 37.53%21.03%16.98%

In the previous week, Genmab A/S had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Genmab A/S and 8 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.12 beat Genmab A/S's score of 0.70 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Takeda Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Genmab A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.09B1.64$712.33M$0.3051.68
Genmab A/S$3.12B5.06$1.14B$1.9912.39

Genmab A/S has a consensus target price of $37.60, suggesting a potential upside of 52.54%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Genmab A/S
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMAB vs. The Competition

MetricGenmab A/SMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.67B$3.11B$5.76B$9.58B
Dividend YieldN/A2.23%4.41%4.10%
P/E Ratio12.3920.8831.1026.04
Price / Sales5.06343.33433.45102.77
Price / Cash16.1043.1937.7358.48
Price / Book2.988.129.536.61
Net Income$1.14B-$54.72M$3.26B$265.56M
7 Day Performance5.75%2.63%2.10%1.97%
1 Month Performance7.78%2.78%2.81%-0.36%
1 Year Performance-9.84%11.01%30.56%19.03%

Genmab A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMAB
Genmab A/S
3.7406 of 5 stars
$24.65
+0.9%
$37.60
+52.5%
-8.8%$15.67B$3.12B12.392,682Positive News
Analyst Downgrade
TAK
Takeda Pharmaceutical
1.5324 of 5 stars
$14.43
-0.1%
N/A+4.3%$45.90B$30.09B48.0847,455Positive News
ARGX
argenex
3.888 of 5 stars
$638.90
-3.5%
$746.81
+16.9%
+27.0%$39.10B$2.25B32.761,599Positive News
ONC
BeOne Medicines
0.6882 of 5 stars
$289.75
+0.5%
$330.89
+14.2%
N/A$31.76B$4.56B-167.4811,000
BNTX
BioNTech
1.7973 of 5 stars
$109.26
-2.1%
$135.91
+24.4%
+27.1%$26.27B$2.98B-68.296,772
INSM
Insmed
4.0104 of 5 stars
$112.89
+3.0%
$112.71
-0.2%
+66.9%$21.42B$398.11M-19.771,271Trending News
Analyst Forecast
Insider Trade
Analyst Revision
SMMT
Summit Therapeutics
2.3858 of 5 stars
$28.25
-1.4%
$34.67
+22.7%
+93.8%$20.98BN/A-83.09110Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.4405 of 5 stars
$16.41
+0.3%
$24.71
+50.6%
+0.4%$18.83B$16.54B-102.5836,830Positive News
ASND
Ascendis Pharma A/S
3.452 of 5 stars
$195.97
+2.3%
$239.80
+22.4%
+39.4%$11.98B$393.54M-37.981,017News Coverage
Analyst Forecast
VTRS
Viatris
1.6454 of 5 stars
$9.86
+1.6%
$10.40
+5.5%
-9.0%$11.57B$14.74B-3.4032,000Analyst Upgrade
RDY
Dr. Reddy's Laboratories
3.1226 of 5 stars
$13.81
+0.0%
$16.95
+22.8%
-12.1%$11.53B$334.26B20.9227,811News Coverage

Related Companies and Tools


This page (NASDAQ:GMAB) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners